Kenvue Reports First Quarter 2026 Results
Business Wire (Thu, 7-May 6:30 AM ET)
Kenvue Declares Quarterly Cash Dividend
Business Wire (Wed, 29-Apr 6:45 AM ET)
Kenvue to Announce First Quarter 2026 Results on May 7, 2026
Business Wire (Thu, 23-Apr 4:32 PM ET)
Kimberly-Clark Announces Post-Closing Organizational Structure and Identifies Key Leadership
PRNewswire (Wed, 15-Apr 8:59 AM ET)
Gross Margin Improvement Highlights Kenvue's Strategic Discipline Amid Sales Pressure and M&A Shift
Market Chameleon (Mon, 3-Nov 5:36 AM ET)
Kimberly-Clark’s $48.7 Billion Kenvue Deal Sets Stage for Global Health and Wellness Giant
Market Chameleon (Mon, 3-Nov 2:07 AM ET)
KVUE Call Spread Buyers Capture 33.7% Gain on Heavy Volume: What’s Driving the Bullish Bet?
Market Chameleon (Fri, 17-Oct 6:37 AM ET)
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
Kenvue trades on the NYSE stock market under the symbol KVUE.
As of June 11, 2026, KVUE stock price climbed to $18.07 with 13,063,893 million shares trading.
KVUE has a beta of -0.32, meaning it tends to be less sensitive to market movements. KVUE has a correlation of 0.01 to the broad based SPY ETF.
KVUE has a market cap of $34.69 billion. This is considered a Large Cap stock.
Last quarter Kenvue reported $4 billion in Revenue and $.32 earnings per share. This beat revenue expectation by $57 million and exceeded earnings estimates by $.06.
In the last 3 years, KVUE traded as high as $26.74 and as low as $14.02.
The top ETF exchange traded funds that KVUE belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
KVUE has underperformed the market in the last year with a return of -12.2%, while the SPY ETF gained +23.6%. In the last 3 month period, KVUE fell short of the market, returning +1.8%, while SPY returned +9.2%. However, in the most recent 2 weeks KVUE has outperformed the stock market by returning +2.1%, while SPY returned -1.7%.
KVUE support price is $17.76 and resistance is $18.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KVUE shares will trade within this expected range on the day.
